FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: DNA

Sort
E.g., 2013-05-25
E.g., 2013-05-25
Enter a comma separated list of user names.

Leading provider of DNA-based security solutions, Applied DNA Sciences, Inc., announced today that it has joined forces with Banknote Watch, government and police companies devoted to fighting the ongoing battle against cash-in-transit (CIT) crimes. The company’s SigNature® DNA marks, which work to dissuade criminals, helps the CIT companies lower costs and minimize risk to their personnel.

Though it’s not getting the frenzy of media attention it received in the past several months, the World Health Organization and Center for Disease Control say the H1N1 (swine flu) is still spreading worldwide and remains a constant threat.

Battered by the financial meltdown, America's business community is anxiously calculating how Tuesday's presidential election will affect it.

EXACT Sciences Corporation (NASDAQ: EXAS), a research and development company focused on developing non-invasive screening technologies for early detection of colorectal cancer, recently announced published results of a comprehensive colorectal cancer detection study in which stool and blood plasma were individually assessed to determine which type of testing was more accurate in detecting the dis

Great Bargains in Ignored Biotech

Posted by MurrayRothbard on August 8th, 2008

There has been a lot of strong recommendations around biotech lately on Contrarian Profits. Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…

Roche offers $43.7B for Genentech

Posted by jesse1290 on July 21st, 2008

Roche Holding has offered to buy the rest of Genentech, about a 44% stake it doesn't already own, for $89 a share, or about $43.7 billion.

The deal would mark one of the Swiss drug maker's biggest acquisitions and would mean about $750 million to $850 million in pre-tax savings.

Pages

ADVERTISE WITH US